Macroeconomic uncertainties could impact spending in academia and biopharma.

For the quarter ended December 2024, 10x Genomics (TXG) reported revenue of $165.02 million, down 10.3% over the same period last year. EPS came in at -$0.40, compared to -$0.41 in the year-ago ...

Genomics (TXG) delivered earnings and revenue surprises of -25% and 0.03%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

PLEASANTON, Calif. AP) — 10x Genomics Inc. TXG) on Wednesday reported a loss of $49 million in its fourth quarter.

Reports Q4 revenue $165.0M, consensus $164.98M. “In 2024, we launched major new products across all three of our platforms and we made changes ...

S&P 500 E-Mini futures (ESH25) are trending down -0.12% this morning as investors braced for the release of key U.S.